AlphAIAlphAI — Financial news for AI agents
marketscreener.comOCT 91 min read

HC Wainwright Downgrades Pacira Biosciences to Neutral, Price Target is $36.50

HC Wainwright downgraded Pacira Biosciences to 'Neutral' with a $36.50 price target. The stock has risen 44.40% in 5 days and 45.50% year-to-date, trading at $36.39 on Nasdaq.

Original reporting
marketscreener.com
Published Oct 9, 2026, 11:37 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 12:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$PCRX
Relevance
7/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

Med
01

Why it matters

The downgrade may trigger short‑term selling pressure, but investors should monitor upcoming earnings or trial updates for longer‑term catalysts.

02

Market read

Analyst rating changes are a common driver of short‑term price moves in biotech stocks.

03

What to watch

Potential upcoming clinical data releases or contract wins that could offset the downgrade.

Relevance 7/10Novelty 6/10Timing: pre‑market today

Background

HC Wainwright issued a new rating and price target for Pacira Biosciences, reflecting its latest valuation outlook.

Market effects

Sector

May weigh on other pain‑management and specialty pharma stocks as analysts reassess valuation multiples.

Regional

Limited to U.S. biotech sector; no broader regional effect.

Global

Minimal global impact beyond niche biotech investors.

Counterpoint

What could challenge this read

If Pacira's pipeline progresses faster than expected, the downgrade could be premature.

Key entities

  • analyst
    HC Wainwright

    Equity research firm providing the downgrade and price target.

  • company
    Pacira Biosciences

    Specialty pharma company focused on pain management.

Read at source← All news

StoryHC Wainwright downgrades Pacira BioSciences to Neutral with $36.50 price target

Also covered by

1 outlet

Related articles

OCT 10
$OPCHMed

Key deals this week: Option Care Health, PTC, Energy Transfer and more

Service Properties Trust (SSVC) received a $2.0B acquisition offer from TKO LLC. Viatris (VTRS) agreed to buy Pacira BioSciences (PCRX) for $1.65B. Option Care Health (OPCH) surged 34% after a $5.8B acquisition deal with CD&R and McKesson (MCK). Energy Transfer (ET) will acquire Vaquero Midstream for $2.625B. Emera (EMA) and Canadian Utilities (CDUAF) agreed to a $10B merger. Cenovus Energy (CVE) will acquire Athabasca Oil (ATHOF) for ~$5.7B.

tradingview.com1 min
OCT 10
$VTRSHighAI 9/10

Viatris to Acquire Pacira Biosciences for USD 1.65 Billion, Adds Exparel, Zilretta to Pain Portfolio

Viatris (VTRS) will acquire Pacira Biosciences (PCRX) for $1.65B, or $36.50 per share, a 44.8% premium. Pacira shares rose 44%, Viatris fell 2%. The deal adds Exparel and Zilretta to Viatris' pain portfolio, with 2025 sales of $575.1M and $116.6M. Viatris plans to fund the deal with cash and short-term borrowings, expecting minimal leverage impact and immediate accretion.

medicaldialogues.in6 min
OCT 9
$VTRSHighAI 9/10

Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio

Viatris (VTRS) agreed to acquire Pacira BioSciences (PCRX) for $1.65B in cash, or $36.50 per share. The deal expands VTRS's pain management portfolio, adding two marketed therapies and a gene therapy candidate. PCRX shares surged 44.4% post-announcement. The transaction is expected to close by the end of 2026 and is anticipated to be immediately accretive to VTRS's financial guidance. Pacira generated $746M in revenue and $177M in adjusted EBITDA in the 12 months ended June 30, 2026.

tradingview.com3 min
OCT 9
$VTRSHighAI 9/10

Viatris to Acquire Pacira in $1.65 Billion Deal

Viatris Inc. will acquire Pacira BioSciences Inc. for $1.65 billion, or $36.50 per share in cash. Pacira's products, EXPAREL and ZILRETTA, are expected to complement Viatris' portfolio and expand its reach in non-opioid pain management. Both companies' CEOs highlighted the strategic benefits of the deal, including accelerated growth and expanded patient access. According to Viatris, the acquisition advances its innovative medicines strategy and adds to its R&D capabilities.

contractpharma.com2 min
OCT 9
$VTRSHighAI 9/10

Viatris inks $1.65B Pacira buyout to build non-opioid pain therapy business

Viatris agreed to buy Pacira BioSciences for $1.65B to expand its non-opioid pain therapy business. Pacira's drugs, Exparel and Zilretta, had combined sales of $708M in the last year. Viatris aims to generate revenue and cost synergies, with peak sales of FAM projected at $500M. The deal is subject to regulatory approval and expected to close by year-end.

biospace.com2 min